From Action for ME – House of Lords debate on severe ME actionforme.org.uk/house-of-… “A House of Lords debate on the treatment of, and research into, severe myalgic encephalomyelitis will take place on Thursday 18 June 2026.” oneagleswings.me.uk #pwME #MECFS

A disease that affects 1 in 8 women was named after the wrong organ for 90 years. Polycystic ovary syndrome put the ovaries in the title. The bigger story is hormonal and metabolic: insulin resistance, rising androgens, weight gain, a steep climb in type 2 diabetes risk. The cysts were never the main event. That naming error has a cost you can measure in referrals. Call it ovarian and she lands in a fertility clinic first, while the blood sugar and insulin side gets looked at late. May 2026: 56 organisations signed a global Lancet consensus and renamed it Polyendocrine Metabolic Ovarian Syndrome. Metabolic is finally in the name. In medicine, the name is the first diagnosis. This one was wrong for three generations.

A scientist spent 30 years studying an organ every textbook said was irrelevant. In 2026, two papers in Nature proved she had been right all along. The papers were not written by her. Her name is Noel Rose Mackay. She is a thymic biologist who has studied the thymus since the 1990s, at a time when the field was considered a professional dead end. The thymus is a small immune organ behind the breastbone. By the 1980s, medical consensus had settled: the thymus trains immune cells in childhood, shrinks at puberty, and stops functioning meaningfully in adults. Researching adult thymic function was considered a waste of time and grant funding. Mackay and a small number of colleagues disagreed. They published research throughout the 1990s and 2000s arguing the thymus remained active in adults and that its ongoing T cell production mattered for immune health. The papers were published in smaller journals, cited rarely, and largely ignored by mainstream medicine. For 30 years, clinical practice did not change. Radiologists reading millions of CT scans did not measure thymic health. Oncologists designing immunotherapy did not account for it. No clinical guideline mentioned it. In March 2026, researchers at Mass General Brigham used artificial intelligence to analyse CT scans from over 25,000 adults. The AI found exactly what Mackay had argued for three decades. Adults with healthier thymuses lived longer. 50% lower risk of death from any cause. 63% lower risk of cardiovascular death. 36% lower risk of lung cancer. In cancer patients receiving immunotherapy, stronger thymic health predicted a 37% lower risk of cancer progression and a 44% lower risk of death. Two papers. Published simultaneously in Nature. Covered by Harvard Medical School, Mass General Brigham, and dozens of international outlets. The researchers who wrote them work in artificial intelligence and cancer imaging. They were not thymic biologists. They were not looking for the thymus. The AI found it for them. The science that spent 30 years being ignored was correct. It took a machine looking at 25,000 scans without any prior assumptions to confirm what a small group of scientists had been saying for three decades. Sometimes the reason a field is underfunded is not that the question is unimportant. It is that the answer is inconvenient.

Exclusive: NHS plans to introduce generalist hospital doctor roles into the health service by the end of the decade, according to a leak of the upcoming 10-Year Workforce Plan. By @HMAnderson39.